



THE
BLADDER CANCER
COMPANY

Photocure ASA: Exercise of employee share options – Correction

Oslo, Norway, 9 June 2021: Reference is made to the stock exchange release by Photocure ASA ("Photocure" or the "Company") published on 7 June 2021 regarding exercise of share options.

The price for option shares sold by primary insiders have been determined at a price of NOK 142.1646 per share.

The primary insiders having exercised options have used the net proceeds from the sale of option shares to purchase shares in Photocure at a price per share of NOK 142.1646 as follows:

- Dan Schneider, CEO, has purchased 18,921 shares
- Erik Dahl, CFO, has purchased 3,405 shares
- Grete Hogstad, VP Global Strategic Marketing & Business Development, has purchased 1,971 shares
- Kari Myren, VP Global Medical Affairs and Clinical Development, has purchased 1,971 shares

The shares are purchased at the stated price from Photocure's holding of own shares. Following the transaction Photocure will hold 21,010 own shares.

Primary insider notifications pursuant to the market abuse regulation article 19 are attached*.

**New attachment*

For further information, please contact:

Photocure
CFO Erik Dahl
Tel: +47 450 55 000
Email: ed@photocure.com

About Photocure ASA

Photocure: The Bladder Cancer Company delivers transformative solutions to improve the lives of bladder cancer patients. Our unique technology, making cancer cells glow bright pink, has led to better health outcomes for patients worldwide. Photocure is headquartered in Oslo, Norway, and listed on the Oslo Stock Exchange (OSE: PHO). For more information, please visit us at www.photocure.com, www.hexvix.com or www.cysview.com

All trademarks mentioned in this release are protected by law and are registered trademarks of Photocure ASA.

This information is subject to the disclosure requirements pursuant to the market abuse regulation article 19 and 5-12 of the Norwegian Securities Trading Act.